Rare Disease Report: Spruce Launches CAH Natural History Study

Yesterday, in observance of Rare Disease Day, Spruce Biosciences announced the launch of the CAH Natural History Study, an initiative to advance knowledge and awareness of congenital adrenal hyperplasia (CAH).

Read More +


Rare Daily by Global Genes: Spruce Begins Natural History Study of Rare Endocrine Disorder CAH

Spruce Biosciences said it has launched a natural history study of congenital adrenal hyperplasia, or CAH, a rare endocrine disorder caused by genetic mutations resulting in the inability to produce the critical stress hormone cortisol.

Read More +





Spruce Biosciences Appoints David Moriarty, Ph.D., as Vice President of Development Operations

Moriarty brings 18 years of clinical industry experience to Spruce to advance SPR001, the company’s lead program for congenital adrenal hyperplasia (CAH), through Phase 2 clinical trials and expand into additional indications

Read More +


Spruce Biosciences Launches Natural History Study for Congenital Adrenal Hyperplasia in Time for World Rare Disease Day

Study Aims to Support Patients, Improve Care and Accelerate Research for Rare Disorder by Putting Power in Patients’ Hands

Read More +



Spruce Biosciences is a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders. We are leveraging our extensive expertise in endocrinology and orphan drug development to meet the significant unmet need of patients suffering from these diseases. We are committed to transforming the quality of life for patients who have been underserved by scientific innovation.